Compare Stocks: TARA, OLMA, ANL, and FTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.01 +1.8%	$12.55	$0.88 ▼ $17.25	$966.61M	1.04	139,923 shs	308,565 shs
FTH Sensei Biotherapeutics	$40.05 +2.7%	$29.86	$7.45 ▼ $41.16	$1.03B	-0.28	295,503 shs	274,991 shs
OLMA Olema Pharmaceuticals	$10.75 +0.2%	$11.42	$6.35 ▼ $36.26	$940.60M	1.98	981,609 shs	505,265 shs
TARA Protara Therapeutics	$3.94 -0.8%	$4.01	$3.02 ▼ $7.82	$232.83M	1.49	356,966 shs	203,006 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+8.61%	+8.45%	+50.85%	+743.26%
FTH Sensei Biotherapeutics	0.00%	+18.35%	+63.60%	+4,004,999,900.00%	+4,004,999,900.00%
OLMA Olema Pharmaceuticals	0.00%	+4.67%	-8.90%	+4.27%	+70.91%
TARA Protara Therapeutics	0.00%	+3.14%	-3.90%	-5.29%	+21.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANL Adlai Nortye	$15.01 +1.8%	$12.55	$0.88 ▼ $17.25	$966.61M	1.04	139,923 shs	308,565 shs
FTH Sensei Biotherapeutics	$40.05 +2.7%	$29.86	$7.45 ▼ $41.16	$1.03B	-0.28	295,503 shs	274,991 shs
OLMA Olema Pharmaceuticals	$10.75 +0.2%	$11.42	$6.35 ▼ $36.26	$940.60M	1.98	981,609 shs	505,265 shs
TARA Protara Therapeutics	$3.94 -0.8%	$4.01	$3.02 ▼ $7.82	$232.83M	1.49	356,966 shs	203,006 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANL Adlai Nortye	0.00%	+8.61%	+8.45%	+50.85%	+743.26%
FTH Sensei Biotherapeutics	0.00%	+18.35%	+63.60%	+4,004,999,900.00%	+4,004,999,900.00%
OLMA Olema Pharmaceuticals	0.00%	+4.67%	-8.90%	+4.27%	+70.91%
TARA Protara Therapeutics	0.00%	+3.14%	-3.90%	-5.29%	+21.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANL Adlai Nortye	2.67	Moderate Buy	$24.25	61.56% Upside
FTH Sensei Biotherapeutics	2.85	Moderate Buy	$55.00	37.33% Upside
OLMA Olema Pharmaceuticals	2.71	Moderate Buy	$42.40	294.42% Upside
TARA Protara Therapeutics	2.75	Moderate Buy	$26.25	566.24% Upside

Current Analyst Ratings Breakdown

Latest TARA, OLMA, ANL, and FTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/17/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OLMA Olema Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$52.00 ➝ $46.00
8/11/2026	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $36.00
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/11/2026	OLMA Olema Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$59.00
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
8/3/2026	OLMA Olema Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANL Adlai Nortye	$5M	193.33	N/A	N/A	$3.34 per share	4.49
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$6.69 per share	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$4.92 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$2.73 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
OLMA Olema Pharmaceuticals	-$162.45M	-$2.12	N/A	N/A	N/A	N/A	-48.26%	-43.04%	11/9/2026 (Estimated)
TARA Protara Therapeutics	-$57.44M	-$1.35	N/A	N/A	N/A	N/A	-41.72%	-38.78%	11/9/2026 (Estimated)

Latest TARA, OLMA, ANL, and FTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TARA Protara Therapeutics	-$0.3257	-$0.36	-$0.0343	-$0.36	N/A	N/A
8/10/2026	Q2 2026	OLMA Olema Pharmaceuticals	-$0.5515	-$0.61	-$0.0585	-$0.61	N/A	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANL Adlai Nortye	0.04	9.55	0.65
FTH Sensei Biotherapeutics	N/A	19.69	19.69
OLMA Olema Pharmaceuticals	0.01	8.86	8.86
TARA Protara Therapeutics	N/A	10.97	10.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANL Adlai Nortye	35.21%
FTH Sensei Biotherapeutics	10.50%
OLMA Olema Pharmaceuticals	91.78%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ANL Adlai Nortye	N/A
FTH Sensei Biotherapeutics	7.00%
OLMA Olema Pharmaceuticals	12.56%
TARA Protara Therapeutics	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANL Adlai Nortye	127	64.40 million	N/A	Not Optionable
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable
OLMA Olema Pharmaceuticals	70	87.50 million	76.51 million	Optionable
TARA Protara Therapeutics	30	59.10 million	54.60 million	Optionable

TARA, OLMA, ANL, and FTH Headlines

Recent News About These Companies

Protara Therapeutics (NASDAQ:TARA) Raised to "Sell" at Wall Street Zen

September 5 at 1:24 AM | americanbankingnews.com

Protara Therapeutics (NASDAQ:TARA) Upgraded to Sell at Wall Street Zen

September 5 at 1:23 AM | marketbeat.com

Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA

August 29, 2026 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 29, 2026 | americanbankingnews.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 29, 2026 | marketbeat.com

Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch

August 21, 2026 | tipranks.com

Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA

August 17, 2026 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen

August 15, 2026 | marketbeat.com

HC Wainwright Issues Negative Forecast for TARA Earnings

August 14, 2026 | marketbeat.com

Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA

August 14, 2026 | marketbeat.com

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

August 12, 2026 | markets.businessinsider.com

Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results

August 11, 2026 | marketbeat.com

Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline

August 11, 2026 | seekingalpha.com

What Makes Protara Therapeutics (TARA) a New Buy Stock

July 21, 2026 | zacks.com

Protara Therapeutics Announces Key Medical Leadership Transition

June 29, 2026 | tipranks.com

Foghorn Therapeutics (FHTX) Receives a Buy from H.C. Wainwright

May 21, 2026 | theglobeandmail.com

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026 | globenewswire.com

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

May 19, 2026 | seekingalpha.com

Protara’s cell therapy shows treatment durability in mid-stage NMIBC study

May 19, 2026 | msn.com

Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program

May 18, 2026 | quiverquant.comQ

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, ANL, and FTH Company Descriptions

Adlai Nortye NASDAQ:ANL

$15.01 +0.26 (+1.76%)

As of 09/4/2026 04:00 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Sensei Biotherapeutics NASDAQ:FTH

$40.05 +1.05 (+2.69%)

As of 09/4/2026 04:00 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Olema Pharmaceuticals NASDAQ:OLMA

$10.75 +0.02 (+0.19%)

As of 09/4/2026 04:00 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Protara Therapeutics NASDAQ:TARA

$3.94 -0.03 (-0.76%)

As of 09/4/2026 04:00 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, OLMA, ANL, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, OLMA, ANL, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, OLMA, ANL, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, ANL, and FTH Company Descriptions

Adlai Nortye NASDAQ:ANL

Sensei Biotherapeutics NASDAQ:FTH

Olema Pharmaceuticals NASDAQ:OLMA

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TARA, OLMA, ANL, and FTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TARA, OLMA, ANL, and FTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TARA, OLMA, ANL, and FTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARA, OLMA, ANL, and FTH Company Descriptions

Adlai Nortye NASDAQ:ANL

Sensei Biotherapeutics NASDAQ:FTH

Olema Pharmaceuticals NASDAQ:OLMA

Protara Therapeutics NASDAQ:TARA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools